Kineta, Inc.
Kineta, Inc. (KA) Stock Overview
Explore Kineta, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
7M
P/E Ratio
-0.96
EPS (TTM)
$-1.64
ROE
0.72%
KA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Kineta, Inc. (KA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.20.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.96 and a market capitalization of 7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
Craig W. Philips
11
219 Terry Ave. N, Seattle, WA
2016